assay standardization comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
==== Choosing low-calorie foods ==== The majority of guidelines agree that a calorie deficit, particularly 500-750 kcal daily, can be recommended to those who want to lose weight. A moderate decrease in caloric intake will lead to a slow weight loss, which is often more beneficial than a rapid weight loss for long term weight management. For example, low fat meats reduce the total amount of calories and cholesterol consumed.
Neurologic examination A systematic clinical assessment of motor, sensory, reflex, and cognitive function to diagnose disorders of the nervous system. Neuromodulation The physiological process by which a given neuron uses chemicals to regulate diverse populations of neurons. May be endogenous (e.g., dopamine) or externally applied via electrical stimulation. Neuromodulator A substance that alters the effectiveness of synaptic transmission without directly causing excitatory or inhibitory postsynaptic potentials. Examples include serotonin, acetylcholine, and norepinephrine. Neuron A specialized cell in the nervous system that transmits electrical and chemical signals. Composed of a cell body, axon, and dendrites. Neuropil A dense network of interwoven nerve fibers, dendrites, and glial processes where synaptic activity occurs, commonly found in the gray matter of the brain. Neuroplasticity See neural plasticity. Neuroprosthetics A field that develops devices that interface with the nervous system to restore lost function, such as cochlear implants or brain–computer interfaces. Neuropsychiatry A medical field combining aspects of neurology and psychiatry to treat disorders with both neurological and psychiatric components, such as OCD or Tourette syndrome. Neuropsychology The study of the relationship between brain function and behavior, often using cognitive testing and brain imaging to assess individuals with brain injury or disease.
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder. This type of sleep apnea is characterized by recurrent episodes of complete or partial obstruction of the upper airway leading to reduced or absent breathing during sleep. These episodes are termed "apneas" with complete or near-complete cessation of breathing, or "hypopneas" when the reduction in breathing is partial. In either case, a fall in blood oxygen saturation, a sleep disruption, or both, may result. A high frequency of apneas or hypopneas during sleep may interfere with the quality of sleep, which – in combination with disturbances in blood oxygenation – is thought to contribute to negative consequences to health and quality of life. The terms obstructive sleep apnea syndrome (OSAS) or obstructive sleep apnea–hypopnea syndrome (OSAHS) may be used to refer to OSA when it is associated with symptoms during the daytime (e.g. excessive daytime sleepiness, decreased cognitive function). Most individuals with obstructive sleep apnea are unaware of disturbances in breathing while sleeping, even after waking up. A bed partner or family member may observe a person snoring or appear to stop breathing, gasp, or choke while sleeping. People who live or sleep alone are often unaware of the condition. Symptoms may persist for years or even decades without identification. During that time, the person may become conditioned to the daytime sleepiness, headaches, and fatigue associated with significant levels of sleep disturbance.
Cardiovascular system: pumping and channeling blood to and from the body and lungs with heart, blood and blood vessels. Digestive system: digestion and processing food with salivary glands, esophagus, stomach, liver, gallbladder, pancreas, intestines, colon, mesentery, rectum and anus. Endocrine system: communication within the body using hormones made by endocrine glands such as the hypothalamus, pituitary gland, pineal body or pineal gland, thyroid, parathyroids and adrenals, i.e., adrenal glands. Excretory system: kidneys, ureters, bladder and urethra involved in fluid balance, electrolyte balance and excretion of urine. Lymphatic system: structures involved in the transfer of lymph between tissues and the blood stream, the lymph and the nodes and vessels that transport it including the immune system: defending against disease-causing agents with leukocytes, tonsils, adenoids, thymus and spleen. Integumentary system: skin, hair and nails of mammals. Also scales of fish, reptiles, and birds, and feathers of birds. Muscular system: movement with muscles. Nervous system: collecting, transferring and processing information with brain, spinal cord and nerves. Reproductive system: the sex organs, such as ovaries, oviducts, uterus, vulva, vagina, testicles, vasa deferentia, seminal vesicles, prostate and penis. Respiratory system: the organs used for breathing, the pharynx, larynx, trachea, bronchi, lungs and diaphragm. Skeletal system: structural support and protection with bones, cartilage, ligaments and tendons.
The 20 countries with the highest prevalence of obesity among adults in 2022 were mostly in the Pacific Islands, the Caribbean, and the Near East and North Africa. In Tonga (71.7 percent), Nauru (69.9 percent), Tuvalu (64.2 percent) and Samoa (62.4 percent), 60 percent or more of the adult population is obese. While the prevalence of adult obesity in the United States of America is the thirteenth-largest in the world (42.0 percent), the country is home to the largest number of obese adults due to its large population, accounting for one-eighth of the global total. The rate of obesity also increases with age at least up to 50 or 60 years old and severe obesity in the United States, Australia, and Canada is increasing faster than the overall rate of obesity. The OECD has projected an increase in obesity rates until at least 2030, especially in the United States, Mexico and England with rates reaching 47%, 39% and 35%, respectively. Once considered a problem only of high-income countries, obesity rates are rising worldwide and affecting both the developed and developing world. These increases have been felt most dramatically in urban settings. In 2021, nearly half the global adult population - a billion men and 1.11 billion women aged 25 or older - were overweight or obese. It was predicted that if these trends continue about 57.4% of men and 60.3% of women would be overweight or obese by 2050. Sex- and gender-based differences influence the prevalence of obesity. Globally there are more obese women than men, but the numbers differ depending on how obesity is measured.
Sources: en.wikipedia.org
He has published extensively on historical demography, focusing especially on long-run changes in multi-generational families, single parenthood, divorce, and marriage, and data and methods for population history. His study of the effects of demographic change on family structure won the William J. Goode Book Award from the American Sociological Association and the Allen Sharlin Memorial Award from the Social Science History Association. Ruggles's work on migration censoring in family reconstitution stimulated a debate about biases introduced by the "Ruggles Effect." Ruggles was also a prominent contributor to the debate about disclosure control in the 2020 U.S. Census. Ruggles received a 2003 Robert J. Lapham Award from the Population Association of America in recognition of lifetime contributions that blend research with the application of demographic knowledge to policy issues, and in 2009 he received the Warren E. Miller Award from the Inter-university Consortium for Political and Social Research for meritorious service to the social sciences. In 1995, Ruggles was described as the "King of Quant" by Wired Magazine, and in 2014, he was named “Wonkblog-Certified Data Wizard” by the Washington Post Wonkblog, which noted that "losing to Steven Ruggles in Name That Data is kind of like losing to Adele on American Idol." In 1994, Ruggles married Lisa Norling, another historian. They have two daughters.
=== Disease entities === In TCM, a disease has two aspects: "bìng" and "zhèng". The former is often translated as "disease entity", "disease category", "illness", or simply "diagnosis". The latter, and more important one, is usually translated as "pattern" (or sometimes also as "syndrome"). For example, the disease entity of a common cold might present with a pattern of wind-cold in one person, and with the pattern of wind-heat in another. From a scientific point of view, most of the disease entities (病; bìng) listed by TCM constitute symptoms. Examples include headache, cough, abdominal pain, constipation etc. Since therapy will not be chosen according to the disease entity but according to the pattern, two people with the same disease entity but different patterns will receive different therapy. Vice versa, people with similar patterns might receive similar therapy even if their disease entities are different. This is called yì bìng tóng zhì, tóng bìng yì zhì (异病同治，同病异治; 'different diseases same treatment', 'same disease different treatments').
=== Off-targeting === Off-targeting is another challenge to the use of siRNAs as a gene knockdown tool. Here, genes with incomplete complementarity are inadvertently downregulated by the siRNA (in effect, the siRNA acts as a miRNA), leading to problems in data interpretation and potential toxicity. This, however, can be partly addressed by designing appropriate control experiments, and siRNA design algorithms are currently being developed to produce siRNAs free from off-targeting. Genome-wide expression analysis, e.g., by microarray technology, can then be used to verify this and further refine the algorithms. A 2006 paper from the laboratory of Anastasia Khvorova implicates 6- or 7-basepair-long stretches from position 2 onward in the siRNA matching with 3'UTR regions in off-targeted genes. The tool of siRNA off-target prediction is available at http://crdd.osdd.net/servers/aspsirna/asptar.php and published as ASPsiRNA resource.
Diagnosis of bone sarcomas begins with a thorough history and physical examination which may reveal characteristic signs and symptoms (see Signs and Symptoms above). Laboratory studies are not particularly useful in diagnosis, although some bone sarcomas (such as osteosarcoma) may be associated with elevated alkaline phosphatase levels, while others (such as Ewing sarcoma) can be associated with elevated erythrocyte sedimentation rate. Importantly, however, none of these laboratory findings are specific to bone sarcomas, meaning that elevations in these lab values are associated with many other conditions as well as sarcoma, and thus cannot be relied upon to conclusively diagnose sarcoma. Imaging studies are critically important in diagnosis, and most clinicians will order a plain radiograph (X-ray) initially. Other imaging studies commonly used in diagnosis include magnetic resonance imaging (MRI) studies and radioisotope bone scans. A CT scan is typically not used in diagnosis of most types of bone sarcoma, although it is an important tool for staging (see below). Definitive diagnosis requires biopsy of the tumor and careful review of the biopsy specimen by an experienced pathologist.
Sources: en.wikipedia.org
=== Liberal revival === Through the 1950s and into the 1960s, the Liberals survived only because a handful of constituencies in rural Scotland and Wales clung to their Liberal traditions, whilst in two English towns, Bolton and Huddersfield, local Liberals and Conservatives agreed to each contest only one of the town's two seats. Jo Grimond, for example, who became Leader of the Liberal Party in 1956, was MP for the remote Orkney and Shetland islands. Under his leadership a Liberal revival began, marked by the Orpington by-election of March 1962 which was won by Eric Lubbock. There, the Liberals won a seat in the London suburbs for the first time since 1935. The Liberals became the first of the major British political parties to advocate British membership of the European Economic Community. Grimond also sought an intellectual revival of the party, seeking to position it as a non-socialist radical alternative to the Conservative government of the day. In particular he canvassed the support of the young post-war university students and recent graduates, appealing to younger voters in a way that many of his recent predecessors had not, and asserting a new strand of Liberalism for the post-war world. The new middle-class suburban generation began to find the Liberals' policies attractive again.
Selenocysteine synthesis occurs on a specialized tRNA, which also functions to incorporate it into nascent polypeptides. The primary and secondary structure of selenocysteine-specific tRNA, tRNASec, differ from those of standard tRNAs in several respects, most notably in having an 8-base-pair (bacteria) or 10-base-pair (eukaryotes) acceptor stem, a long variable region arm, and substitutions at several well-conserved base positions. The selenocysteine tRNAs are initially charged with serine by seryl-tRNA ligase, but the resulting Ser-tRNASec is not used for translation because it is not recognised by the normal translation elongation factor (EF-Tu in bacteria, eEF1A in eukaryotes).
International Proteolysis Society MEROPS - the peptidase database Archived 2006-11-14 at the Wayback Machine List of protease inhibitors Protease cutting predictor List of proteases and their specificities (see also [1] Archived 2011-04-30 at the Wayback Machine) Proteolysis MAP from Center for Proteolytic Pathways Proteolysis Cut Site database - curated expert annotation from users Protease cut sites graphical interface TopFIND protease database covering cut sites, substrates and protein termini Proteases at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Keratinization of sulcular epithelium === Although the inherent nature of the sulcular epithelium is non-keratinised, studies have discovered the potentiality of sulcular epithelium to keratinise under certain environmental conditions. It was shown that when exposed to the environment of the gingival surface, the sulcular epithelium develops into a keratinised squamous epithelium similar to that on the regular outer surface of the gingiva.
=== Sample preparation === As a significant step in conducting a Western blot, sample preparation has to be done effectively since the interpretation of this assay is influenced by the protein preparation, which is composed of protein extraction and purification processes. To achieve efficient protein extraction, a proper homogenization method needs to be chosen due to the fact that it is responsible for bursting the cell membrane and releasing the intracellular components. Besides that, the ideal lysis buffer is needed to acquire substantial amounts of target protein content because the buffer is leading the process of protein solubilization and preventing protein degradation. After completing the sample preparation, the protein content is ready to be separated by the utilization of gel electrophoresis.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.